[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 8 of about 8
1. Spectre G, Gural A, Amir G, Lossos A, Siegal T, Paltiel O: Central nervous system involvement in indolent lymphomas. Ann Oncol; 2005 Mar;16(3):450-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in indolent lymphomas.
  • BACKGROUND: Central nervous system (CNS) involvement, a well-recognized complication of aggressive non-Hodgkin's lymphomas (NHL), has rarely been reported in indolent lymphomas.
  • PATIENTS AND METHODS: We retrospectively reviewed the disease characteristics and clinical course in seven patients (six females, one male) with indolent B-cell lymphomas who developed CNS involvement during various stages of their illness.
  • RESULTS: The median ages at diagnosis of systemic and CNS lymphoma were 60 and 63 years, respectively.
  • Histologies were: small lymphocytic lymphoma (two), follicular lymphoma grade I (two), follicular lymphoma grade II (two) and unclear low-grade histology (one).
  • Systemic lymphoma was found in all patients, all but one having bone marrow involvement.
  • Four patients had a transformation to high-grade histology.
  • Six patients were treated with systemic and intra-cerebrospinal fluid chemotherapy, and two received radiotherapy as well.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642707.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C: Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res; 2009 Jun 15;15(12):4038-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
  • PURPOSE: To investigate the activity of SAR3419, a novel humanized anti-CD19 antibody (huB4), conjugated to a cytotoxic maytansine derivative N(2)'-deacetyl-N(2)'-(4-mercapto-4-methyl-1-oxopentyl) maytansine, in preclinical xenograft models for non-Hodgkin's lymphoma.
  • EXPERIMENTAL DESIGN: Antitumor activity of SAR3419 was assessed as a single agent and in comparison with conventional therapies using a subcutaneous model for diffuse large B-cell lymphoma (WSU-DLCL2) and a systemic model for follicular small cleaved cell lymphoma (WSU-FSCCL) in mice with severe combined immune deficiency.
  • RESULTS: Our results showed that in these chemotherapy-resistant models, SAR3419 was more effective than CHOP (cyclophosphamide-Adriamycin-vincristine-prednisone) regimen or rituximab.
  • Only treatment with SAR3419 led to survival of the whole group of animals to the end of the experiment (150-155 days) in both models.
  • Treatment with rituximab resulted in antitumor activity in both models comparable with the low dose of SAR3419.
  • Necropsy and tissue staining in the WSU-FSCCL systemic model revealed that all deaths featured leptomeningeal lymphoma in the control and treated groups.
  • Interestingly, some of the animals that survived to the end of the experiment and seemed healthy at time of euthanasia did show microscopic evidence of lymphoma.
  • CONCLUSIONS: Overall, SAR3419 is a very active immunotoxin in preclinical models for human B-cell lymphoma and holds promise as a novel and well-tolerated therapy in B-cell non-Hodgkin's lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Immunoconjugates / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Maytansine / analogs & derivatives. Maytansine / therapeutic use
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. Antigens, CD19 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Line, Tumor. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Immunologic Factors / therapeutic use. Mice. Mice, SCID. Prednisone / therapeutic use. Rituximab. Vincristine / therapeutic use. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19509168.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD19; 0 / Antineoplastic Agents, Phytogenic; 0 / Immunoconjugates; 0 / Immunologic Factors; 0 / N2'-deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine; 14083FR882 / Maytansine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


3. Jacobsen E, Chen JH, Schurko B, Benson C, Oh WK: Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report. Cases J; 2009;2:7273
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report.
  • An asymptomatic 67-year-old man presented with a left supraclavicular lymph node that enlarged over a 2-month period which was biopsied.
  • Pathologic features were consistent with involvement by metastatic seminoma and follicular lymphoma, follicular pattern, grade 1 (of 3).
  • Staging Positron Emission Tomography/Computed Tomography scans indicated several areas of enlarged lymph nodes.
  • The patient completed chemotherapy with bleomycin, etoposide, and cisplatin chemotherapy.
  • This is the first reported case of metastatic seminoma and follicular lymphoma occurring in the same lymph node.
  • Given the natural history of these two malignancies, if this patient develops recurrent lymphadenopathy, it will be difficult to identify whether the enlarged lymph nodes represent recurrent seminoma or follicular lymphoma without a biopsy of each pathologically enlarged node.
  • Similarly, Fluorodeoxyglucose- Positron Emission Tomography is known to be active in both seminoma and follicular lymphoma, making this scan non-specific in this patient.
  • Finally, this patient had no baseline elevation in any germ cell tumor marker.
  • Thus, serum tumor markers cannot be relied upon as surrogates for response to chemotherapy or as identifiers of relapsed seminoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ Clin Evid. 2007;2007. pii: 1807 [19454048.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):825-37, vii-viii [18954739.001]
  • [Cites] World J Urol. 2004 Apr;22(1):41-6 [15024601.001]
  • [Cites] J Intern Med. 1994 Jul;236(1):91-2 [8021579.001]
  • [Cites] Semin Hematol. 2008 Jul;45(3 Suppl 2):S2-6 [18760706.001]
  • (PMID = 19918516.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769346
  •  go-up   go-down


Advertisement
4. Lichtman SM, Petroni G, Schilsky RL, Johnson JL, Perri RT, Niedzwiecki D, Sklar J, Barcos M, Peterson BA: High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. Leuk Lymphoma; 2001 Nov-Dec;42(6):1255-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
  • The main objectives of this study were to determine the feasibility of administering high doses of cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) every 14-21 days to patients with follicular small cleaved cell lymphoma.
  • For each patient, the treatment was not considered feasible if fewer than four cycles of cyclophosphamide chemotherapy could be administered on schedule (i.e. at least every 29 days) or (1) hospitalization of the patient for longer than three days was necessary for neutropenic fever (38 degrees C) or bacteriologically documented infection in > 50% of the cycles, or (2) grade > or = 2 hemorrhage in association with thrombocytopenia of grade > or = 3 severity occurred in > 50% of the cycles or (3) non-hematologic toxicity (excluding nausea/vomiting and alopecia) of grade > or = 3 occurred in > 50% of cycles.
  • The goal was to have a treatment program feasible in 75% or more of the treated patients.
  • The secondary objectives were to determine the toxicities, the complete and partial response rates, and the time to treatment failure (TTF).
  • The trial also attempted to assess the effectiveness of this treatment program in eradicating Bcl-2 rearrangements by PCR, and to assess complete remission duration in relationship to PCR results in patients who respond to this chemotherapy program.
  • Patients were required to have histologically documented non-Hodgkin's lymphoma of the subtypes follicular, predominantly small cleaved cell (IWF-B) or follicular mixed, (IWF-C).
  • The median follow-up time is 5.0 years, with a range of 2.5-6.7 years.
  • The 1-year estimated probability of freedom from treatment failure was 50% and of survival at 1 year was 92%.
  • Post-treatment specimens were submitted for seven of the 13 patients.
  • Four of the seven converted to Bcl-2 negative following treatment.
  • Eight of 13 Bcl-2 positive patients (62%) had a clinical response to treatment.
  • This study demonstrates that repetitive doses of cyclophosphamide at 4.5 g/m2 every two weeks with rhG-CSF support can be administered to selected younger patients with advanced follicular lymphoma with morphologic involvement of the bone marrow with acceptable non-hematologic toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Lymphoma, Follicular / drug therapy. Lymphoma, Non-Hodgkin / drug therapy


5. Rohatgi N, LaRocca RV, Bard V, Sethuraman G, Foon KA: Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. Am J Hematol; 2002 Jul;70(3):181-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
  • Advanced follicular lymphomas, grades I and II, are indolent tumors but are not considered curable with standard therapy.
  • However, fludarabine-based combination chemotherapy regimens have been associated with significant myelotoxicity.
  • Patients with bulky stage II, stage III, or stage IV follicular lymphoma (grade I or II) were entered on this protocol.
  • Response was assessed after the 3(rd) cycle of fludarabine and after the 4(th), 6(th), and 8(th) cycles of CNOP.
  • The sequential combination of fludarabine and CNOP appears to be active and well tolerated in patients with grade I and II follicular lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Lymphoma, Follicular / drug therapy. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Vidarabine / administration & dosage. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12111762.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; MCOP protocol
  •  go-up   go-down


6. Jacobsen E, Lomo L, Briccetti F, Longtine J, Freedman A: Follicular lymphoma with bilateral testicular and epididymal involvement: case report and review of the literature. Leuk Lymphoma; 2005 Nov;46(11):1663-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular lymphoma with bilateral testicular and epididymal involvement: case report and review of the literature.
  • Testicular involvement with indolent lymphoma is extremely rare, particularly in the absence of transformation to an aggressive histology.
  • Histologic examination of lymph node, bone marrow, and testicular/epididymal biopsies revealed involvement with grade I follicular lymphoma.
  • The patient was started on chemotherapy with cyclophosphamide, vincristine, prednisone, and rituximab in addition to intrathecal methotrexate and testicular radiation.
  • He is now 6 months into therapy and responding well.
  • A review of the literature demonstrated this to be the first confirmed case of testicular and epididymal involvement with grade I follicular lymphoma.
  • [MeSH-major] Epididymis / pathology. Lymphoma, Follicular / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Lymph Nodes / pathology. Lymphatic Irradiation. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236619.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


7. Mantadakis E, Samonis G: Common symptoms--different diseases: coexistence of neurosyphilis and non-Hodgkin's lymphoma. Infection; 2002 Jan;30(1):43-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common symptoms--different diseases: coexistence of neurosyphilis and non-Hodgkin's lymphoma.
  • We describe the case of a 32-year-old man with generalized lymphadenopathy who was diagnosed with a low-grade follicular small-cleaved cell lymphoma.
  • The patient developed hearing loss, tinnitus and cerebrospinal fluid (CSF) pleocytosis attributed to central nervous system (CNS) infiltration by his malignancy, while receiving chemotherapy with vincristine, cyclophosphamide and prednisone.
  • Despite intrathecal chemotherapy with methotrexate, the CSF pleocytosis persisted.
  • Neurosyphilis was suspected because of prior history of gonorrhea and was confirmed with serologic studies of blood and CSF and from the decline of the anti-treponemal antibody titers with appropriate antibiotic therapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / complications. Neurosyphilis / complications. Neurosyphilis / diagnosis

  • Genetic Alliance. consumer health - Neurosyphilis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11876517.001).
  • [ISSN] 0300-8126
  • [Journal-full-title] Infection
  • [ISO-abbreviation] Infection
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Matsuo T, Ichimura K, Shinagawa K, Yoshino T: Different histopathological types of orbital lymphoma 16 years after systemic follicular lymphoma: immunohistochemical and immunogenetic analyses of two cases. J Clin Exp Hematop; 2008 Apr;48(1):17-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different histopathological types of orbital lymphoma 16 years after systemic follicular lymphoma: immunohistochemical and immunogenetic analyses of two cases.
  • The purpose of this study is to show that the histopathological type of an orbital lymphoma can differ from the systemic follicular lymphoma that precedes it.
  • A 44-year-old man (Patient #1) and a 50-year-old man (Patient #2) presented with generalized lymphadenopathy due to grade 1 follicular lymphoma proven on lymph node biopsy.
  • Patient #1 was followed without treatment for 16 years when he developed a right orbital mass.
  • Patient #2 underwent several courses of combination chemotherapy as well as radiation but relapsed.
  • The second biopsy of the lymph node nine years later showed the same histopathological type of follicular lymphoma.
  • He developed an orbital mass on the right side 16 years after the initial presentation.
  • In Patient #1, excisional biopsy of the orbital masses showed extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
  • In Patient #2, biopsy revealed the orbital mass to be T-cell/histiocyte-rich diffuse large B-cell lymphoma.
  • In conclusion, orbital lymphomas can occur as a second lymphoma with a different histopathological type in the long-term follow-up of systemic lymphomas.
  • The original and subsequent lymphomatous lesions may or may not share neoplastic cell clonality and all genomics.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Follicular / pathology. Neoplasms, Second Primary / pathology. Orbital Neoplasms / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Orbital lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18434689.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement